Skip to main navigation

Investor Relations

Investors & Media
Contact Us
Careers

Overview
News / Events
Company
Financial
Stock
SEC Filings
Governance

Overview
News / Events
Company
Financial
Stock
SEC Filings
Governance

Press Releases

Year

Dec 01, 2021

BioXcel Therapeutics Announces Extension of FDA Review Period of its NDA for BXCL501 for the Acute Treatment of Agitation Associated with Schizophrenia and Bipolar Disorders

Nov 11, 2021

BioXcel Therapeutics to Present at the 2021 Jefferies London Healthcare Conference

Nov 10, 2021

BioXcel Therapeutics Reports Third Quarter 2021 Financial Results and Recent Operational Highlights

Oct 27, 2021

BioXcel Therapeutics to Report Third Quarter 2021 Financial Results on November 10, 2021

Oct 18, 2021

BioXcel Therapeutics Announces Expansion of Phase 2 Trial of BXCL701 in De Novo and Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer

Sep 23, 2021

BioXcel Therapeutics to Highlight Novel Approaches in AI-Based Drug Candidate Discovery and Development and Advances in Neuroscience Portfolio at Virtual R&D Day

Sep 15, 2021

BioXcel Therapeutics Presents Results from Ongoing Phase 2 Trial of BXCL701 in Combination with KEYTRUDA® in Aggressive Forms of Prostate Cancer at ESMO

Sep 12, 2021

BioXcel Therapeutics to Present Updates from Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2021 ESMO Congress

Sep 09, 2021

BioXcel Therapeutics to Host Virtual R&D Day on September 23, 2021

Aug 10, 2021

BioXcel Therapeutics Reports Second Quarter 2021 Financial Results and Recent Operational Highlights

Pagination

Current page 1
Page 2
Page 3
Page 4
Next page
Last page

Displaying 1 - 10 of 35

Site - Investor Tools

Print Page

Tear Sheet

Email Alerts

RSS Feeds

Contacts

Search

About Us
Our Pipeline
Our Science
Patients & Advocacy

Investors & Media
Contact Us
Careers

Copyright © 2021 BioXcel Therapeutics, Inc. All Rights Reserved.

Privacy Policy
Disclaimer
Sitemap